{
  "success": true,
  "command": "SRPT EQ DES",
  "data": {
    "timestamp": "2025-10-01T21:25:49.589967Z",
    "window_id": "3779-window",
    "ticker": "SRPT US",
    "company_info": {
      "company_name": "Sarepta Therapeutics Inc",
      "asset_class": "EQ",
      "logo_url": "https://api.twelvedata.com/logo/sarepta.com",
      "website": "https://sarepta.com/",
      "address": "215 FIRST STREET, SUITE 415, CAMBRIDGE, MA, 02142",
      "ceo": "CEO: MR. DOUGLAS S. INGRAM ESQ., J.D."
    },
    "description": "Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Childrens Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.",
    "eps_estimates": {},
    "analyst_ratings": [
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Outperform",
        "Old_Target": "$50",
        "New_Target": "$50",
        "Date": "09/22/25 12:19"
      },
      {
        "Firm": "Guggenheim",
        "Analyst": "Debjit Chattopadhyay",
        "Rating": "Buy",
        "Old_Target": "$22",
        "New_Target": "$22",
        "Date": "09/15/25 13:41"
      },
      {
        "Firm": "Leerink Partners",
        "Analyst": "Joseph Schwartz",
        "Rating": "Market Perform",
        "Old_Target": "$12",
        "New_Target": "$15",
        "Date": "09/09/25 19:00"
      },
      {
        "Firm": "HC Wainwright & Co.",
        "Analyst": "Mitchell S. Kapoor",
        "Rating": "Sell",
        "Old_Target": "$5",
        "New_Target": "$5",
        "Date": "08/25/25 16:36"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Old_Target": "$17",
        "New_Target": "$16",
        "Date": "08/21/25 22:45"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Old_Target": "$10",
        "New_Target": "$17",
        "Date": "08/20/25 17:45"
      },
      {
        "Firm": "Deutsche Bank",
        "Analyst": "David Hoang",
        "Rating": "Sell",
        "Old_Target": "$6",
        "New_Target": "$12",
        "Date": "08/15/25 22:39"
      },
      {
        "Firm": "Wells Fargo",
        "Analyst": "Yanan Zhu",
        "Rating": "Overweight",
        "Old_Target": "$48",
        "New_Target": "$50",
        "Date": "08/07/25 19:51"
      },
      {
        "Firm": "Goldman Sachs",
        "Analyst": "Salveen Richter",
        "Rating": "Neutral",
        "Old_Target": "$10",
        "New_Target": "$19",
        "Date": "08/07/25 22:38"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Old_Target": "$10",
        "New_Target": "$22",
        "Date": "07/30/25 18:05"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Old_Target": "$10",
        "New_Target": "$22",
        "Date": "07/29/25 22:56"
      },
      {
        "Firm": "Bernstein",
        "Analyst": "William Pickering",
        "Rating": "Market Perform",
        "Old_Target": "",
        "New_Target": "",
        "Date": "07/29/25 20:30"
      },
      {
        "Firm": "JP Morgan",
        "Analyst": "Anupam Rama",
        "Rating": "Neutral",
        "Old_Target": "",
        "New_Target": "",
        "Date": "07/29/25 15:55"
      },
      {
        "Firm": "Piper Sandler",
        "Analyst": "Biren Amin",
        "Rating": "Neutral",
        "Old_Target": "$11",
        "New_Target": "$15",
        "Date": "07/29/25 17:09"
      },
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Market Perform",
        "Old_Target": "$25",
        "New_Target": "$50",
        "Date": "07/29/25 19:32"
      },
      {
        "Firm": "Oppenheimer",
        "Analyst": "Hartaj Singh",
        "Rating": "Outperform",
        "Old_Target": "$30",
        "New_Target": "$37",
        "Date": "07/29/25 16:15"
      },
      {
        "Firm": "Morgan Stanley",
        "Analyst": "Matthew Harrison",
        "Rating": "Equal-Weight",
        "Old_Target": "$15",
        "New_Target": "$20",
        "Date": "07/29/25 16:58"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Underweight",
        "Old_Target": "$18",
        "New_Target": "$10",
        "Date": "07/27/25 23:02"
      },
      {
        "Firm": "Wells Fargo",
        "Analyst": "Yanan Zhu",
        "Rating": "Overweight",
        "Old_Target": "$65",
        "New_Target": "$48",
        "Date": "07/24/25 18:30"
      },
      {
        "Firm": "Citigroup",
        "Analyst": "Yigal Nochomovitz",
        "Rating": "Sell",
        "Old_Target": "",
        "New_Target": "",
        "Date": "07/24/25 15:33"
      },
      {
        "Firm": "Jefferies",
        "Analyst": "Andrew Tsai",
        "Rating": "Buy",
        "Old_Target": "$40",
        "New_Target": "$35",
        "Date": "07/24/25 21:13"
      },
      {
        "Firm": "B of A Securities",
        "Analyst": "Tazeen Ahmad",
        "Rating": "Underperform",
        "Old_Target": "$20",
        "New_Target": "$10",
        "Date": "07/23/25 16:11"
      },
      {
        "Firm": "Barclays",
        "Analyst": "Gena Wang",
        "Rating": "Equal-Weight",
        "Old_Target": "$32",
        "New_Target": "$18",
        "Date": "07/22/25 15:45"
      },
      {
        "Firm": "BMO Capital",
        "Analyst": "Kostas Biliouris",
        "Rating": "Market Perform",
        "Old_Target": "$50",
        "New_Target": "$25",
        "Date": "07/22/25 21:06"
      },
      {
        "Firm": "Piper Sandler",
        "Analyst": "Biren Amin",
        "Rating": "Neutral",
        "Old_Target": "$18",
        "New_Target": "$11",
        "Date": "07/22/25 18:49"
      }
    ],
    "snapshot": {
      "Exchange": "XNGS",
      "Currency": "USD",
      "Float": "87.6M",
      "Employees": "1,372",
      "Insiders": "4.66%",
      "Institutions": "81.75%",
      "P/Sales": "0.81",
      "P/Book": "1.39",
      "EV/EBITDA": "60.95",
      "EV/R": "0.99",
      "EV": "2.4B",
      "Trl P/E": "19.98x",
      "Fwd P/E": "1.68x",
      "Trl Yld": "-",
      "Fwd Yld": "-",
      "5Y Avg Yld": "-",
      "Payout R": "-",
      "Ex Div Date": "-",
      "Div Date": "-",
      "Beta": "0.49",
      "Short": "20.3M",
      "Short R": "3.59"
    }
  }
}